Patients with CX3CL1 overexpressing tumours showed a significantly shorter progression-free survival (PFS) than the low-expressing group (median 15.5 vs. 20 months; HR 1.44, 95% CI 1.04-2.00; P = 0.026; Fig. 1C). The gene discussed is CX3CL1; the disease is neoplasm.